Compare Paycom Software Inc (PAYC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Paycom Software Inc trades at $139 (market cap $6.72B), while Vertex Pharmaceuticals Incorporated trades at $472.52 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.2× Paycom Software Inc's market cap, and Paycom Software Inc pays a 1.04% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| PAYC | VRTX | |
|---|---|---|
Market Cap | $6.72B | $122.33B |
Sector | Technology | Health |
52-Week High | $238.80 | $529.59 |
52-Week Low | $113.59 | $366.54 |
Enterprise Value | $7.33B | $117.07B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paycom Software (PAYC) trades at $144.22, down 2.51% today, with a bullish technical signal and strong fundamentals including 22.44% net margin and 37.15% ROE. Recent earnings beat expectations in Q1 2026, and the company launched a new Asset Management tool. Cash flow from operations grew to $679M in 2025, though net cash flow declined from 2024's peak.
Outlook remains positive with analyst consensus near current price ($144.60 target) and 47% buy ratings. Risks include high P/B of 8.6 and reliance on HR software demand. The stock offers value with a reasonable P/E of 17.33 but faces execution risks in maintaining growth against competition.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
